Kaletra
 |
|
| Combination of | |
|---|---|
| Lopinavir | Protease inhibitor |
| Ritonavir | Protease inhibitor (pharmacokinetic booster) |
| Clinical data | |
| Trade names | Kaletra, Aluvia |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a602015 |
| Pregnancy category |
|
| Routes of administration |
By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| NIAID ChemDB | |
  (what is this?)
|
|
Lopinavir/ritonavir (LPV/r), sold under the brand name Kaletra among others, is a fixed dose combination medication for the treatment and prevention of HIV/AIDS. It combines lopinavir with a low dose of ritonavir. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. It is taken by mouth as a tablet or solution.
Common side effects include diarrhea, vomiting, feeling tired, headaches, and muscle pains. Severe side effects may include pancreatitis, liver problems, and high blood sugar. It is commonly used in pregnancy and it appears to be safe. Both medications are HIV protease inhibitors. Ritonavir functions by slowing down the breakdown of lopinavir.
Lopinavir/ritonavir as a single medication was approved for use in the United States in 2000. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is 18.96 to 113.52 a month. In the United States it is not available as a generic medication and costs more than 200 USD for a typical month supply as of 2016.
As of 2006, lopinavir/ritonavir forms part of the preferred combination for first-line therapy recommended by the US United States Department of Health and Human Services in 2006.
...
Wikipedia